LungCancerRx 🫁💊
@LungCancerRx
Followers
888
Following
4K
Media
40
Statuses
3K
✍️ Prescribing empowerment, knowledge & hope in #lungcancer | 🤝 Team @adesaimd @fawziaburous @lungoncdoc | 🫶 #lcsm #ESMO25
#lcsm
Joined May 2023
🎙️ The latest episode with @christine_lovly is now available!! You’re going to want to listen to this one as our “prescription for knowledge” for patients with EGFR positive lung cancer continues! @EGFRResisters @ADesaiMD @FawziAbuRous @lungoncdoc
EGFR+ NSCLC treatment is evolving — how do you explain it to patients? In this LungCancerRx episode, @lungoncdoc, @ADesaiMD, @FawziAbuRous & @christine_lovly break down the latest data and how to communicate complex options with clarity. 🎧 https://t.co/JuiemoWb4U
#LungCancerRx
0
4
14
Honored to present at @sitcancer for HARMONi-A trial final OS. 😃Echo @HTawbi_MD that we are marking evolution of PD-1 blockade. @MDAndersonNews @lungoncdoc @oncodaily @OncoViews
Dr. @LeXiuning presenting @sitcancer FINAL OS results from ivonescimab + carbo/pem in TKI-refractory EGFR-NSCLC, HR 0.74, p=0.019. Benefit strongest in pts with brain mets HR 0.61, regimen approved in China. Impressive results marking evolution of PD-1 blockade
3
15
54
When the sample you sent for tissue profiling comes back QNS @BalazsHalmosMD @marklewismd
when the oxygen you weaned is back on overnight
1
1
12
Such an important 🔑 initiative to provide the latest information for patients and their care partners impacted by #SCLC! In this session, we discuss everything related to antibody-drug conjugates (#ADCs) & their role in SCLC: 🧑🔬 MOA: biological chemo “missile” 🎯 Targets:
🎬 Exciting behind-the-scenes moment! Brittany recorded the Small Cell Lung Cancer Patient Education Program 2025–26 with Dr. @drshieldsmd today. This new video series will bring patients and caregivers the latest information about small cell lung cancer in an easy-to-understand
1
4
24
Super excited to support @neerajaiims for a well deserved spot on the @ASCO Nominating Committee!! @HemOncFellows @LungCancerRx
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
1
2
15
Just got back from #WorldCancerCongress2025 in Muscat 🇴🇲 where I presented on EGFR+ #NSCLC & joined a panel on patient navigation and education in cancer care, hosted by @ICPC_Global. Great connections across #MENA. Grateful to @OmanCancer for the invite! #LungCancer #Oncology
0
2
12
@ShaniqueMD put an incredible amount of work into bringing this together!! I’m so proud to co-mentor her, alongside @maraantonoff, on this young-onset lung cancer study. #WTS25
Important exploration of surgical outcomes in young pts (<50 yrs) with lung cancer beautifully presented by @ShaniqueMD at #WTS25 Efforts led by @maraantonoff and @lungoncdoc Nice discussion from @IanCBostock1
0
5
15
🚨 So proud of @pedroabrahao16, a talented medical student from #Brazil, and his fantastic mentor #EricSaldanha for presenting their work at #ISLB25 Pedro also earned a #travelaward! 🏆✨ A remarkable achievement and an inspiring example of early-career excellence! Go give
1
7
29
Our collaborative work led by @alissajcooper and @BZhangMD reviewing outcomes with tarlatamab in EGFR-transformed SCLC. HUGE unmet need, as this is a population often w/ poor outcomes and excluded from many clinical trials. @EGFRResisters @MDAndersonNews @MSKCancerCenter
Disappointing early look at tarlatamab in #EGFR NSCLC after #SCLC transformation @JCOPO_ASCO from @alissajcooper et al. Small numbers but out of 14, only 1 response (7%). May reflect heavy pretreatment and PS but optimism somewhat tempered here. https://t.co/7GKaaXgHp2
0
5
32
Opening our @isliquidbiopsy 7th annual mtg! with @ChristianRolfo @UmbertoMalapel1 @drgandara @edgardo_ny #lungcancer #lcsm @ElJanLe @MJOSESERRANO19
1
13
30
Grateful to have represented @HenryFordHealth at the @globalhealthexh 2025 in #Riyadh 🇸🇦 alongside Dr. @UMossallam, Dr. Raed Alnajjar, @IsmailAbushaik1, & Morris Blake. I participated in a thought-provoking panel discussion on #lungcancer screening, early detection, and
0
3
27
November 1st marks the start of #LungCancerAwarenessMonth. ▫️ANYONE with lungs can get lung cancer. ▫️NO ONE deserves it. Grateful for my incredible team @MDAndersonNews, because community & teamwork make all the difference. 🤍
3
6
60
Unfortunately, while DLL3 is widely expressed (93%+) in tumors post-SCLC transformation ( https://t.co/ySAC2zeX7g), it is not clearly an actionable or biologically relevant target for transformed SCLC. This is similar to EGFR alterations and anti-PD-1/PD-L1 therapies, despite high
Disappointing early look at tarlatamab in #EGFR NSCLC after #SCLC transformation @JCOPO_ASCO from @alissajcooper et al. Small numbers but out of 14, only 1 response (7%). May reflect heavy pretreatment and PS but optimism somewhat tempered here. https://t.co/7GKaaXgHp2
3
20
77
New study: 94% pts w/ lung cancer searched online; only 1 in 4 got patient-friendly info from their team. Nearly all said simplified trial summaries improved understanding. Let’s make research accessible for all. 🔗 https://t.co/LQbQcu94zC
@FawziAbuRous @ADesaiMD @jillfeldman4
3
17
62
A true giant in the field of small cell lung cancer! An absolute honor to have Dr. Anish Thomas (@NIH) as a visiting professor at @IUCancerCenter, presenting his groundbreaking research with a “reverse translational” approach (patient bedside to the bench, and back!) on #SCLC.
1
8
32
Thank you so much for sharing your thoughts/experience and your work around this @jillfeldman4! I am myself guilty of focusing on COCOON & SKIPIRR “just” as “AE management” rather than also appreciating the ⬆️ in QoL! With Ami-Laz, I always use this slide as a reference!
Fantastic, thoughtful discussion between @OncBrothers & @lungoncdoc about 1st line treatment options for #EGFR #NSCLC. Having options that have significant OS benefits is amazing, but all regimens have toxicities. Every lung #onc should not just prescribe treatment, but also
1
18
62
Updated data on combination options seen at #ESMO25 for metastatic non-small cell lung cancer w/ EGFR mutated disease. Stuck w/ cross trial comparisons for now! We touched on this data and our options 👇👇 with @lungoncdoc! @EGFRSummit #OncTwitter #lcsm @OncoAlert @OncUpdates
In our “Challenging Cases” discussion on metastatic NSCLC mEGFR w/ @lungoncdoc we touch on: ✅ Rx options ✅ AE management ✅ Sequencing Full discussion: ⭐️ https://t.co/XFMkB6kxmY ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter @OncUpdates
2
31
80
@OncBrothers @lungoncdoc @EGFRSummit @OncoAlert @OncUpdates @LungCancerRx @ipreeshagul @alshamsi2000 @BijoyTelivala @RenoHemonc @dr_yakupergun @FawziAbuRous @T4Cancer @AnaVManana @jillfeldman4 Really nice review! financial toxicity remains a concern for many patients in the United States, particularly those with high co-pays or limited insurance coverage.
0
1
6
Congrats to @YYElamin on #NORTHSTAR #ESMO25 Thoughts: 1️⃣Osi+LCT=longer control (25.3 v 17.5 mo; 34% ↓ progression) 2️⃣Surgery feasible in stage IV (41%) 3️⃣ Polymetastatic pts benefited w/ complete LCT 4️⃣Complete LCT ~2x longer control (27.9 v 14.5 mo) 5️⃣No added tox/pneumonitis
2
6
31